BAYRY News and Press, Bayer AG ADR From 11/08/23

2023-11-08 02:03:18 ET More on Bayer AG Bayer Stock: Good Value For Money Bayer: Undervalued With Clear Catalysts Bayer: Still A Strong Buy Despite Lowered Guidance Bayer slapped with $332M jury verdict in Roundup cancer trial Twist Bioscience inks an...

2023-11-07 17:07:59 ET Summary Our 3-step process focuses on wide-moat stocks (as per Morningstar’s rating). We are only interested in those targets that are attractively valued in historical comparison. We share the heat map of the most investable candidates that may b...

2023-11-01 06:42:04 ET Summary Bayer's Monsanto unit ordered to pay $332M to plaintiff in Roundup cancer trial. Real estate stocks slump as NAR and brokerages found guilty of inflating commission rates. WeWork planning to file for bankruptcy next week, with shares down 39% pre...

2023-11-01 02:29:27 ET Summary VanEck Agribusiness ETF provides investors with exposure to agribusiness sector. MOO has a long history of underperforming the S&P 500. The agribusiness is generally challenging due to high levels of competition. Investors who want long e...

2023-10-31 19:53:11 ET More on Bayer Bayer Stock: Good Value For Money Bayer: Undervalued With Clear Catalysts Bayer: Still A Strong Buy Despite Lowered Guidance For further details see: Bayer slapped with $332M jury verdict in Roundup cancer trial

2023-10-27 14:46:40 ET Summary Bayer's stock is undervalued and offers potential for long-term recovery. Revenues have been quite strong for a while. But earnings have not shown sustainable growth. Key growth stimuli include resolving glyphosate issues and new drugs, but risks...

2023-10-19 07:26:46 ET More on Roche Roche: Positive Readouts From Pipeline Roche: 2023 Should Mark The Bottom Roche: FX Drug But Positive Outlook Roche in pact with Monte Rosa to develop cancer and neuro drugs Data shows Genentech's Fenebrutinib redu...

2023-10-13 10:15:00 ET Summary We are value investors. In constructing portfolios for our clients, we seek out companies that we believe are trading in the market at significant discounts to their underlying value. These businesses must offer significant profit potential and be run by...

2023-10-09 12:37:47 ET Summary Our 3-step process focuses on wide-moat stocks (as per Morningstar’s rating). We are only interested in those targets that are attractively valued in historical comparison. We share the heat map of the most investable candidates that may b...

2023-10-05 12:10:43 ET More on Bayer Bayer: Undervalued With Clear Catalysts Twist Bioscience: Progress Hidden By Execution Issues And Soft Demand Bayer: Still A Strong Buy Despite Lowered Guidance FMC, Bayer downgraded to Neutral at Redburn Atlantic on crop-...